Cellvizio utilization continues to expand globally in established and emerging clinical indications Paris and Boston, April 29, 2024 – 5:45 p.m....
Full Year 2023 Sales increased +42%1 to €10.5m €1.2m positive full-year operating income +47% growth in Q1 2024 in U.S PPU volume Recent Telix...
Renewed EIB confidence in Mauna Kea extending support until 2029 Final maturities deferred 4 years to 2028 and 2029 Alignment of debt maturities...
Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers...
Paris, Boston, and London, March 27, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from...
Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health & wellness industry ...
Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Record-high PPU Growth of +109%1 in Q4 2023, Full Year PPU Growth of +57%1 Tasly and Telix Partnerships Remain On-Track Partnership Pipeline...
Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a ~19% stake in Mauna Kea Technologies...
Ongoing enrollment of over 200 patients across 7 sites in Europe and the U.S. Paris and Boston, November 2, 2023 – 08:00 a.m. CET...
Strong performance thanks to partnership revenue and U.S. growth +40% increase in Q3 U.S. PPU revenue Strong convergence of current and upcoming...
